Medidur FAME enrolment passes half way mark

Article

Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.

Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.

FAME is a double-masked, randomized, multicentre study that will follow around 900 patients across the US, Canada, Europe and India for 36 months, studying the efficacy and safety of Medidur.

Medidur is an injectable intravitreal insert that is designed to deliver low doses of fluocinolone acetonide to the retina over a period of up to three years, as a treatment for diabetic macular oedema (DME). Using a proprietary 25-gauge transconjunctival injector system, Medidur is inserted into the vitreous during an outpatient procedure.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.